PEGILODECAKIN PLUS ANTI-PD-1 IS TOLERABLE AND EFFECTIVE

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2019年 / 9卷 / 11期
关键词：
D O I：
10.1158/2159-8290.CD-RW2019-152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pegilodecakin plus anti-PD-1 showed tolerability and efficacy in some advanced solid tumors. ©2019 American Association for Cancer Research.
引用
收藏
页码：1482 / 1482
页数：1
相关论文
共 50 条
  • [1] Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-PD-1
    Garon, E.
    Wong, D.
    Schneider, J.
    Aliumaily, R.
    Korn, W.
    Infante, J.
    Patel, M.
    Autio, K.
    Papadopoulos, K.
    Naing, A.
    Gabrail, N.
    Munster, P.
    Goldman, J.
    Hung, A.
    Van Vlasselaer, P.
    Leveque, J.
    Oft, M.
    Spigel, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S366 - S367
  • [2] Overall responses and survival in RCC on pegilodecakin with anti-PD-1
    Naing, A.
    Infante, J. R.
    Wong, D. J.
    Korn, W. M.
    Aljumaily, R.
    Papadopoulos, K. P.
    Autio, K. A.
    Pant, S.
    Bauer, T. M.
    Drakaki, A.
    Daver, N. G.
    Hung, A.
    Verma, R.
    Ratti, N.
    McCauley, S.
    Van Vlasselaer, P.
    Tannir, M.
    Oft, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 110 : S1 - S2
  • [3] Anti-PD-1 antibodies: effective in GCTs?
    Rebecca Kelsey
    [J]. Nature Reviews Urology, 2016, 13 (5) : 238 - 238
  • [4] Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
    Tannir, N. M.
    Naing, A.
    Papadopoulos, K. P.
    Wong, D. J.
    Korn, W. M.
    Aljumaily, R.
    Autio, K. A.
    Pant, S.
    Bauer, T. M.
    Drakaki, A.
    Daver, N.
    Hung, A.
    Oft, M.
    Leveque, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 401 - 401
  • [5] Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient
    Gao, Song
    Wang, Jiaqian
    Zhu, Zhongzheng
    Fang, Juemin
    Zhao, Yu
    Liu, Zhuqing
    Qin, Huanlong
    Wei, Yuquan
    Xu, Heng
    Dan, Xu
    Yang, Li
    Xu, Qing
    [J]. IMMUNOTHERAPY, 2023, 15 (02) : 57 - 70
  • [6] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
    Li, Mengqian
    [J]. LANCET ONCOLOGY, 2021, 22 (08): : E342 - E342
  • [7] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [8] Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.
    Garon, Edward B.
    Schneider, Jeffrey Gary
    Wong, Deborah J. L.
    Aljumaily, Raid
    Korn, Wolfgang Michael
    Infante, Jeffrey R.
    Patel, Manish R.
    Autio, Karen A.
    Papadopoulos, Kyriakos P.
    Naing, Aung
    Gabrail, Nashat Y.
    Munster, Pamela N.
    Goldman, Jonathan Wade
    Hung, Annie
    Van Vlasselaer, Peter
    Leveque, Joseph
    Oft, Martin
    Spigel, David R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma reply
    da Silva, Ines Pires
    Ahmed, Tasnia
    Reijers, Irene L. M.
    Warner, Allison Betof
    Patrinely, James Randall
    Serra-Bellver, Patricio
    Allayous, Clara
    Mangana, Joanna
    Zimmer, Lisa
    Trojaniello, Claudia
    Klein, Oliver
    Gerard, Camille L.
    Michielin, Olivier
    Haydon, Andrew
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Lebbe, Celeste
    Lorigan, Paul
    Johnson, Douglas B.
    Sandhu, Shahneen
    Lo, Serigne N.
    Menzies, Alexander M.
    Long, Georgina, V
    [J]. LANCET ONCOLOGY, 2021, 22 (08): : E343 - E344
  • [10] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
12345